NAD+ Benefits: What the Human Evidence Actually Supports

Written by the Nuvirox Research Team

Short answer: the one NAD+ benefit that's well proven in humans is that good precursors raise NAD+ itself — everything beyond that is a set of promising but unconfirmed signals. NAD+ powers energy metabolism and fuels repair-and-signaling enzymes, and it drops with age, so the theory behind supplementing it is reasonable. In trials, raising NAD+ has been linked to lower blood pressure and arterial stiffness, improved muscle insulin sensitivity, and better aerobic capacity — but each of those comes from early, often small studies in particular groups, and at least one careful trial found nothing. The fair reading: real biological signals, not yet settled health outcomes.

What does NAD+ actually do in the body?

NAD+ is a coenzyme present in every cell, and it wears two hats. First, it's a workhorse of energy metabolism, shuttling electrons through the reactions that turn food into usable cellular fuel. Second, it's a substrate — fuel — for enzymes involved in DNA repair and cellular signaling, including the sirtuins and PARPs. When NAD+ runs low, both jobs get harder. Because NAD+ levels fall with age, the hope is that restoring them supports the cellular housekeeping that slows down over time. That's the mechanistic case; the rest of this article is about how much of it shows up in actual human results.

What human studies actually show

This is where marketing and evidence need to be pulled apart. Below are placebo-controlled human trials — including one that found nothing — grouped by the benefit people care about.

The foundation: precursors reliably raise NAD+. The largest controlled trial gave 140 healthy overweight adults 100, 300, or 1000 mg of NR or placebo for 8 weeks, and whole-blood NAD+ rose dose-dependently — about 22%, 51%, and 142% — within two weeks and stayed up (Conze et al., 2019). On the NMN side, a 12-week placebo-controlled trial in 30 healthy adults found 250 mg/day was safe and significantly increased whole-blood NAD+ (Okabe et al., 2022). Before any "benefit" claim, this is the part that's solid.

Vascular signals: lower blood pressure and arterial stiffness. In a crossover trial of 30 healthy middle-aged and older adults, six weeks of 1000 mg/day NR raised NAD+ by roughly 60% and, in preliminary analyses, tended to lower systolic blood pressure and aortic stiffness — with the largest blood-pressure reductions in participants who started in the elevated range (Martens et al., 2018). These were secondary, exploratory findings, which is why the same group launched a larger dedicated trial to test them properly.

Metabolic signal: muscle insulin sensitivity. A 10-week placebo-controlled trial gave 250 mg/day of NMN to 25 postmenopausal women with prediabetes and measured muscle insulin sensitivity directly with a clamp; the NMN group improved and placebo didn't (Yoshino et al., 2021). Two honest caveats travel with it: muscle NAD+ content itself didn't measurably change, and a published critique flagged a baseline difference between the groups (Brenner, 2021). It's a positive result that still deserves scrutiny.

Exercise signal: aerobic capacity. A six-week randomized trial in 48 amateur runners tested 300, 600, or 1200 mg/day of NMN alongside training. Aerobic capacity improved at the 600 and 1200 mg/day doses, apparently through better oxygen utilization in muscle, with no improvement in the placebo group (Liao et al., 2021). Promising for active people — though it's a single trial in trained runners, not proof for the general population.

And the null result the marketing skips. A 12-week trial gave 40 obese, insulin-resistant men a high 2000 mg/day dose of NR. It was safe — but it did not improve insulin sensitivity, glucose metabolism, energy expenditure, or body composition (Dollerup et al., 2018). This is the single most important counterweight in the whole NAD+ story: raising NAD+ does not automatically deliver a metabolic benefit, and the population and dose decide a lot.

So is the "energy" benefit real?

It's the most-marketed claim and the least cleanly proven. NAD+ is central to cellular energy production, so the rationale is intuitive — but "my mitochondria use NAD+" is biochemistry, not a guarantee you'll feel more energetic. The closest human evidence is indirect: the aerobic-capacity trial in runners (Liao et al., 2021) suggests a performance signal in trained people, while the metabolic trial in obese men found no change in energy expenditure (Dollerup et al., 2018). The honest position is that a felt energy boost is plausible for some and unproven as a general effect — and if your energy problem is medical, that deserves attention first.

What NAD+ won't do (and when to check with a doctor)

It won't reverse aging, and it isn't a treatment for any disease. Benefits demonstrated in a specific group — prediabetic women, trained runners, adults with above-normal blood pressure — may not transfer to a healthy person with no baseline issue. The strongest claim the data support across the board is modest: precursors raise NAD+ and are generally well tolerated.

If you're drawn to NAD+ because of ongoing fatigue, low mood, or cardiovascular worry, those symptoms can have real medical causes — thyroid issues, anemia, sleep disorders, depression, blood-pressure conditions — that warrant a proper evaluation. See a doctor before treating a symptom with a supplement, particularly if it's new, worsening, or accompanied by other changes. For tolerability specifics, see our review of NAD+ supplement side effects.

Frequently asked questions

What's the single best-supported benefit of NAD+ supplements?
That a quality precursor reliably raises blood NAD+, the coenzyme that declines with age. The downstream health benefits are promising signals rather than settled facts.

Will NAD+ lower my blood pressure?
One small crossover trial found a trend toward lower blood pressure and arterial stiffness, strongest in people who started elevated (Martens et al., 2018). It's an encouraging signal being tested in larger trials, not an established treatment — manage blood pressure with your doctor.

Does NAD+ help with exercise?
In one trial, NMN improved aerobic capacity in amateur runners at higher doses (Liao et al., 2021). That's a single study in trained people, so treat it as promising rather than proven.

Why did one study show no benefit?
A 12-week trial in obese, insulin-resistant men using 2000 mg/day NR found no metabolic improvement (Dollerup et al., 2018). It's a reminder that raising NAD+ and improving health outcomes are two different things, and that more isn't automatically better.

NR or NMN for these benefits?
Both raise NAD+; the benefit trials are split across them. Which precursor matters less than dose and consistency — see NR vs. NMN vs. NAD+ and our overview of nicotinamide mononucleotide.

The bottom line

The honest hierarchy of NAD+ benefits looks like this: rock-solid that precursors raise NAD+ and are well tolerated; promising but unconfirmed that this lowers blood pressure and arterial stiffness, improves muscle insulin sensitivity in some groups, and supports aerobic capacity; and unproven that it reverses aging or boosts everyone's energy. A null trial in the literature keeps the whole picture grounded. If you want the foundational effect with realistic expectations, that's a reasonable case for a quality precursor — paired with the understanding that the bigger promises are still being earned in the lab. For the broader category overview, start with our guide to NAD+ supplements.

References

1. Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep. 2019;9(1):9772. DOI: 10.1038/s41598-019-46120-z.
2. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. DOI: 10.1038/s41467-018-03421-7.
3. Okabe K, Yaku K, Uchida Y, et al. Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Front Nutr. 2022;9:868640. DOI: 10.3389/fnut.2022.868640. PMCID: PMC9036060.
4. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. DOI: 10.1126/science.abe9985. PMID: 33888596.
5. Brenner C. Comment on "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;373(6554):eabj1696. DOI: 10.1126/science.abj1696. PMID: 34326206.
6. Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021;18(1):54. DOI: 10.1186/s12970-021-00442-4. PMCID: PMC8265078.
7. Dollerup OL, Christensen B, Svart M, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr. 2018;108(2):343–353. DOI: 10.1093/ajcn/nqy132. PMID: 29992272.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.